Alexandre Avila
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Brain Metastases and Treatment, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain(2018)1,297 cited
- → Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis(2018)651 cited
- → Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer(2016)276 cited
- → Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis(2017)258 cited
- → Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.(2017)126 cited
- → Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article(2011)47 cited
- → Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors(2019)39 cited
- → Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma(2015)36 cited
- → Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma(2014)23 cited
- → Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).(2017)6 cited